| Name | Title | Contact Details |
|---|---|---|
Gerardo Escalera |
Director Information Technology/CIO | Profile |
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
At UnitedHealthcare we`re dedicated to helping people live healthier lives and helping to make the health system work better for everyone by simplifying the health care experience, meeting consumer health needs and sustaining trusted relationships with care providers. These are extraordinary times in health care. The opportunities to help people live healthier have never been greater. Advanced data and technologies, breakthrough treatments and consumer choice are redefining what can be achieved. At UnitedHealthcare, part of the UnitedHealth Group family of businesses, we are working to create a system that is connected, aligned and more affordable for all involved; one that delivers high quality care, responsive to the needs of each person and the communities in which they live. With connections to more than 1.3 million physicians and care professionals and 6,200+ hospitals and care facilities across the globe, we can collaborate in new ways to improve patient care while providing customizable and comprehensive solutions in any market place, anywhere. Our Values Integrity: Honor commitments. Never compromise ethics. Compassion: Walk in the shoes of people we serve and those with whom we work. Relationships: Build trust through collaboration. Innovation: Invent the future, learn from the past. Performance: Demonstrate excellence in everything we do.
Hyperion Technology Group is a defense and space company based in Madrid, Spain.
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
AppliedVR is the leader in therapeutic virtual reality, transforming healthcare through the power of pixels. Since its founding in 2015, appliedVR has delivered scientifically designed and validated digital health solutions to over 20,000 patients in more than 250 hospitals and in 8 countries globally.